Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | JSKN003 |
Synonyms | |
Therapy Description |
JSKN003 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting two epitopes of ERBB2 (HER2) linked to a topoisomerase inhibitor, which potentially induces cell cycle arrest and apoptosis of ERBB2 (HER2)-expressing tumor cells and results in antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr 3038), NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JSKN003 | JSKN 003|JSKN-003 | HER2 (ERBB2) Antibody 75 HER2 (ERBB2) Antibody-Drug Conjugate 29 | JSKN003 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting two epitopes of ERBB2 (HER2) linked to a topoisomerase inhibitor, which potentially induces cell cycle arrest and apoptosis of ERBB2 (HER2)-expressing tumor cells and results in antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr 3038), NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05494918 | Phase I | JSKN003 | First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors | Recruiting | AUS | 0 |